Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial

KEY POINTS: Ixazomib treatment resulted in decreases in B-cell subsets and bone marrow lymphocytes. Ixazomib treatment resulted in modest decreases in certain anti-HLA antibody specificities. Ixazomib treatment was tolerated, with modest adverse events. BACKGROUND: Ixazomib is a second-generation or...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Nancy, Reese, Shannon, Ptak, Lucy, Aziz, Fahad, Parajuli, Sandesh, Jucaud, Vadim, Denham, Shari, Mishra, Ameet, Cascalho, Marilia, Platt, Jeffrey L., Hematti, Peiman, Djamali, Arjang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Nephrology 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371382/
https://www.ncbi.nlm.nih.gov/pubmed/36951387
http://dx.doi.org/10.34067/KID.0000000000000113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371382/
https://www.ncbi.nlm.nih.gov/pubmed/36951387
http://dx.doi.org/10.34067/KID.0000000000000113

Ejemplares similares